 | ||||||||||||
|
| Sanofi, KaloBios Get Fast-Track Designation For KB001A to Treat Bacterial ... Sanofi (SNY) and its partner KaloBios Pharmaceuticals (KBIO) said the U.S. Food and Drug Administration has granted fast-track designation for the investigation of KB001A, an antibody fragment, intended for protection against bacterial pneumonia caused ... Wall Street Journal - Tue, 23 Apr 2013 06:03 | |
| US FDA fast-track for Sanofi Pasteur's KB001A; orphan status for Teva/Xenon's ... The Pharma Letter - Tue, 23 Apr 2013 08:22 | |
| U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios' Novel ... SYS-CON Media (press release) - Tue, 23 Apr 2013 05:03 | |
| Causes of Pneumonia The most common causes of pneumonia are infections caused by: bacteria — the most common cause of pneumonia in adults viruses — often responsible for pneumonia in children. canada.com. mycoplasma — organisms that have characteristics of bacteria ... NewsDay - Fri, 10 May 2013 21:01 | |
| Pfizer takes its shot at a vaccine for evasive superbug But the bacterium can cause a range of diseases from boils and impetigo to raging blood infections and deadly bacterial pneumonia. The discovery of penicillin in 1928 gave doctors a way to defeat staph infections, but overuse and misuse gave rise to ... Chicago Tribune - Wed, 22 May 2013 22:26 | |
 | Cubist's experimental antibiotic drug to get priority review from FDA for use ... The company said it received fast-track status from the Food and Drug Administration for ceftolozane/tazobactam, also known as CXA-201, in treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, along with ... Boston.com - Tue, 07 May 2013 13:45 |
| UPDATE: FDA Grants Fast Track Designation for Cubist's Late-Stage Antibiotic ... Benzinga - Tue, 07 May 2013 05:35 | |
| Cubist receives Fast Track designation from FDA for late-stage antibiotic ... News-Medical.net - Tue, 07 May 2013 23:34 | |
| Cubist antibiotic regimen gets fast-track review MSN Money - Tue, 07 May 2013 10:58 | |
| Combination Antibiotic Gets Fast-Tracked for Serious Infections Monthly Prescribing Reference - Tue, 07 May 2013 07:06 | |
| Cubist: FDA Grants Fast-Track Status to Antibiotic Candidate Wall Street Journal - Tue, 07 May 2013 06:14 | |
 | Death of 8-month-old son of Phila. couple who shun medicine ruled homicide Brandon Schaible, infant son of Herbert and Catherine Schaible, reportedly died on April 18th from dehydration and bacterial pneumonia stemming from a streptococcus infection. The Schaibles have worked as teachers at their fundamentalist church, the ... CBS News - Wed, 22 May 2013 13:06 |
| Philadelphia faith-healing parents charged in death of baby Chicago Tribune - Wed, 22 May 2013 16:08 | |
| Parents who chose prayer over hospital for sick son charged for murder KPLC-TV - Wed, 22 May 2013 16:34 | |
| Parents Herbert and Catherine Schaible were on probation after their 2-year ... Daily Mail - Wed, 22 May 2013 15:20 | |
| Prayer Couple Charged 3rd Degree Murder; Wild Strip Club Shooting Video ... iradiophilly.com - Wed, 22 May 2013 15:48 | |
| Faith-Healing Couple Charged With Murder In Infant's Death The Inquisitr - Wed, 22 May 2013 14:25 | |
| Faith-Healers' Child Death Ruled As Homicide Sky News - Wed, 22 May 2013 02:45 | |
| Bacterial coinfections often found in viral-associated hospitalizations “The occurrence of staphylococcal and pneumococcal pneumonia complicating influenza pandemics is well recognized,” the researchers wrote in the Journal of Infectious Diseases. “Although temporal associations between bacterial pneumonia and ... Healio - Wed, 15 May 2013 08:48 | |
| Stop Smoking to Reduce Risk of Pneumonia in HIV+ HIV-positive smokers are at high risk of contracting bacterial pneumonia - a common and serious lung infection in people living with HIV - compared to their non-smoking counterparts. An analysis of previous studies published in the journal BMC Medicine ... AllAfrica.com - Fri, 26 Apr 2013 01:51 | |
| Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety ... CHAPEL HILL, N.C., May 20, 2013 /PRNewswire via COMTEX/ -- Cempra, Inc. (NASDAQ:CEMP) , a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, ... MarketWatch (press release) - Mon, 20 May 2013 05:02 | |